NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Centre for Health Technology Evaluation

# Technology Appraisal Committee D meeting minutes

**Minutes: C**onfirmed

**Date:** Wednesday 6 November 2024

**Location:** Via Zoom

## Attendees

Committee members present

1. Professor Amanda Adler (Chair – Items 1.1 to 4.2) Items 1.1 to 4.2, 5.1.3 to 5.2.2
2. Dr Raju Reddy (Chair – Items 4.2.1 to 5.2.2) Present for all items
3. Martin Bradley Present for all items
4. Dr Matthew Bradley Items 1.1 to 4.2.2
5. Paul Caulfield Present for all items
6. Professor Sofia Dias Present for all items
7. Andrew Fox Present for all items
8. Dr Robert Hodgson Present for all items
9. Dr Bernard Khoo Present for all items
10. Sue Wen Leo Present for all items
11. Dr Guy Makin Present for all items
12. Dr Philip Mallender Present for all items
13. Professor David Meads Present for all items
14. Giles Monnickendam Present for all items
15. Carole Pitkeathley Present for all items
16. Dr Ben Searle Present for all items
17. Sophia Steer Present for all items
18. Dr Will Sullivan Present for all items
19. Dr Savvas Vlachos Present for all items
20. Dr Salman Waqar Present for all items
21. Dr Zenas Yiu Items 5.1.1 to 5.2.2

*Dr Megan John (Observing) 1.1 to 4.1.3, 5.1 to 5.2.2*

NICE staff (key players) present

Ian Watson, Associate Director Items 1.1 to 4.2.2

Leena Issa, Project Manager Items 1.1 to 4.2.2

Michelle Green, Heath Technology Assessment Adviser Items 1.1 to 4.2.2

Thomas Palmer, Heath Technology Assessment Analyst Items 1.1 to 4.2.2

Ross Dent, Associate Director Items 5.1 to 5.2.2

Louise Jafferally, Project Manager Items 5.1 to 5.1.3

Kate Moore, Project Manager Items 5.1.3 to 5.2.2

Lizzie Walker, Heath Technology Assessment Adviser Items 5.1 to 5.2.2

Owen Swales, Heath Technology Assessment Analyst Items 5.1 to 5.2.2

External assessment group representatives present

Nigel Armstrong, Kleijnen Systematic Reviews Items 1.1 to 4.1.3

Maiwenn Al, Kleijnen Systematic Reviews Items 1.1 to 4.1.3

Marie Westwood, Kleijnen Systematic Reviews Items 5.1 to 5.1.3

Sabine Grimm, Kleijnen Systematic Reviews  Items 5.1 to 5.1.3

Clinical, Patient & NHS England experts present

Fiona Dignan, Consultant Haematologist - Clinical expert, nominated by NHSE Items 1.1 to 4.1.3

Donal McLornan, Consultant in Haematology and Stem Cell Transplantation - Clinical expert, nominated by Novartis Items 1.1 to 4.1.3

Elsa Bennett - Patient expert, nominated by Anthony Nolan Items 1.1 to 4.1.3

Kenneth Dawson - Patient expert, nominated by Anthony Nolan Items 1.1 to 4.1.3

Elizabeth Coulthard, Professor of Cognitive Neurology - Clinical expert, nominated by Alzheimer’s Research UK Items 5.1 to 5.1.3

Richard Perry, Consultant Neurologist and Honorary Senior Lecturer - Clinical expert, nominated by Eisai Items 5.1 to 5.1.3

David Thomas, Head of Policy - Access & Innovation, Alzheimer’s Research UK - Patient expert, nominated by Alzheimer’s Research UK Items 5.1 to 5.1.3

Larry Woelk, Patient expert, nominated by Alzheimer’s Research UK Items 5.1 to 5.1.3

Rita Woelk, Partner of patient expert Larry Woelk Items 5.1 to 5.1.3

Ann Jarvis, Commissioning expert, nominated by NHS England Items 5.1 to 5.1.3

Ewan Maule, Commissioning expert, nominated by NHS North East and North Cumbria ICB Items 5.1 to 5.1.3

Sanjeev Patel, IMF Lead, NHS England Items 5.1 to 5.2.2

*Please note that alongside the attendees listed in this document, there were additional NICE Staff present in this meeting. These attendees were not involved in the decision making or discussions.*

## Minutes

### Introduction to the meeting

* 1. The Chair, Professor Amanda Adler, welcomed members of the committee and other attendees present to the meeting.
  2. The Chair noted apologies from Craig Cook, Dr Nathan Moore and Dr Zenas Yiu.

### News and announcements

* 1. None

### Minutes from the last meeting

* 1. The committee approved the minutes of the committee meetings held on Wednesday 7 August 2024, Wednesday 4 September 2024 and Thursday 3 October 2024.

### Appraisal of Ruxolitinib for treating acute graft versus host disease refractory to corticosteroids in people aged 12 and over [ID6377]

* 1. Part 1 – Open session
     1. The Chair welcomed the invited experts, external assessment group representatives, members of the public and company representatives from Novartis.
     2. The Chair asked all committee members and experts, external assessment group representatives and NICE staff present to declare any relevant interests in relation to the item being considered. Declarations for this appraisal can be found on the Topic Register of Interest (TROI) on the topic webpage, [here](https://www.nice.org.uk/guidance/indevelopment/gid-ta11512/documents).
     3. The Chair led a discussion of the evidence presented to the committee. This information was presented to the committee by Professor David Meads, Dr Bernard Khoo and Paul Caulfield.
  2. Part 2 – Closed session (company representatives, clinical and patient experts, external assessment group representatives and members of the public were asked to leave the meeting)
     1. The committee then agreed on the content of the Draft Guidance (DG) or Final Draft Guidance (FDG). The committee decision was reached through a vote by members.
     2. The committee asked the NICE technical team to prepare the Draft Guidance (DG) or Final Draft Guidance (FDG) in line with their decisions.
* Further updates will be available on the topic webpage in due course: <https://www.nice.org.uk/guidance/indevelopment/gid-ta11512>

### Appraisal of Lecanemab for treating mild cognitive impairment or mild dementia caused by Alzheimer’s disease [ID4043]

* 1. Part 1 – Open session
     1. The Chair, Dr Raju Reddy, welcomed the invited experts, external assessment group representatives, members of the public and company representatives from Eisai.
     2. The Chair asked all committee members and experts, external assessment group representatives and NICE staff present to declare any relevant interests in relation to the item being considered. Declarations for this appraisal can be found on the Topic Register of Interest (TROI) on the topic webpage, [here](https://www.nice.org.uk/guidance/indevelopment/gid-ta11220/documents).
     3. The Chair led a discussion of the consultation comments presented to the committee. This information was presented to the committee by Dr Raju Reddy.
  2. Part 2 – Closed session (company representatives, clinical, patient and two NHSE experts, external assessment group representatives and members of the public were asked to leave the meeting)
     1. The committee then agreed on the content of the Draft Guidance (DG) or Final Draft Guidance (FDG). The committee decision was reached by consensus.
     2. The committee asked the NICE technical team to prepare the Draft Guidance (DG) or Final Draft Guidance (FDG) in line with their decisions.
* Further updates will be available on the topic webpage in due course: <https://www.nice.org.uk/guidance/indevelopment/gid-ta11220>

### Date of the next meeting

The next meeting of the Technology Appraisal Committee D will be held on Thursday 5 December 2024 and will start promptly at 9.00am.